Ambition Trial Coordinating Centre Private Bag 320, Princess Marina Hospital Gaborone, Botswana

Γ



Laboratory Work Practice Document: 4 Cryptococcal Antigen Lateral Flow Assay					
Title of study	Meningitis Induction Therapy in	High Dose AMBISOME <sup>©</sup> on a Fluconazole Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Phase III Randomized Controlled Non-inferiority Trial			
Acronym	Ambition-cm – AMBIsome Thera	Ambition-cm – AMBIsome Therapy Induction OptimizatioN			
ISRCTN No.:	ISRCTN72509687	ISRCTN72509687			
WPD Current version	Version 1.0 02/08/2017	Version 1.0 02/08/2017			
Author(s)	Kwana Lechiile Lab Scientist	Huana Fectivit	02/08/2017		
	Timothée Boyer Chammard Clinical Advisor		02/08/2017		
Reviewer(s)	David Lawrence Lead clinician	De	02/08/2017		
	Aude Sturny-Leclere Lab Technician, Institut Pasteur	State	02/08/2017		
Approved by	Joseph Jarvis Cl	J.N.J.	02/08/2017		
Revision History:					

Revision History:				
Version Number	Effective Date	Reason for Change		
1.0		First version		



## Laboratory Working Practice Document 4: Cryptococcal Antigen Lateral Flow Assay

#### Purpose

This document describes the standard operating procedure (SOP) for the Immy CrAg lateral flow assay

#### References

CrAg Lateral Flow Assay package insert

#### Appendices

CrAg Lateral Flow Assay package insert

The CrAg Lateral Flow Assay is an immunochromatographic test system for the detection of the capsular polysaccharide antigens of *Cryptococcus* species complex (*Cryptococcus neoformans* and *Cryptococcus gattii*) in serum, plasma, and cerebral spinal fluid (CSF).

#### MATERIALS

- 1. LF Specimen Diluent (2.5 mL): Glycine-buffered saline containing blocking agents and a preservative
- 2. LF Titration Diluent (6.0 mL): Glycine-buffered saline containing a preservative
- 3. CrAg LF Test Strips (50 strips in desiccant vial)
- 4. CrAg Positive Control (1 mL): Glycine-buffered saline spiked with cryptococcal antigen reference strain

#### STORAGE

The entire kit should be at room temperature (22-25 °C) before and during use.

### PROCEDURE

- 1. Write down the ID, number or REF sample on each micro-centrifuge of the corresponding sample.
- 1. Add 1 drop of LF Specimen Diluent (REF GLF025) to an appropriate reservoir (disposable micro-centrifuge

AMBITION-cm


tube, test tubes, or micro-titer plate, etc.).

- 2. Add 40  $\mu\text{L}$  of specimen to the container and mix.
- 3. Submerge the white end of a Cryptococcal Antigen Lateral Flow Test Strip into the specimen.
- 4. Wait 10 minutes, At room temperature (on the bench).

5. Read and record the results. The presence of two lines (test and control), regardless of the intensity of the

test line, indicates a positive result.

A single control line indicates a negative result. If the control line does not appear, the results are invalid and the test should be repeated.



The assay has been validated for serum, plasma, and CSF only.

For more information, go to:

- https://vimeo.com/53970336
- https://vimeo.com/54390554



# Laboratory Working Practice Document 4: Cryptococcal Antigen Lateral Flow Assay

### Training

Each staff member receives or has direct access to applicable Working Practice Documents (WPDs).

Each staff member reviews the applicable WPDs once a year.

All WPD training is documented and tracked in the training log located in the Investigator Site File (ISF)

New staff is trained on applicable WPDs within 30 days of employment and all WPDs within 90 days of employment.

Staff members whose duties fall within this WPD scope are retrained within 14 days of the approval of each WPD revision.



# Laboratory Working Practice Document 4: Cryptococcal Antigen Lateral Flow Assay

Staff signatures: (signing below indicates that you have read this SOP and understand the material contained in it)

Date	Name (Please print)	Signature